CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions

Stock Information for CytoSorbents Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CytoSorbents Corporation

CytoSorbents Provides Regulatory Update for DrugSorb-ATR
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.